2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1432

Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1702

Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 999

Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1005

Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1202

Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1044

TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1121

The Association Between Physician Sex and Faculty Rank Among Academic Rheumatologists in the United States

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1388

The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1239

The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1562

The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1582

The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1681

The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1637

The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1647

The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1333

The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].